Cellular medicine company, Mesoblast
(ASX:MSB) has announced that Shawn Cline Tomasello has joined its Board of Directors.
She brings more than 30 years of experience in the pharmaceutical and biotech industries to the company.
Tomasello’s most recent position was with Kit Pharma, where she played a pivotel role in the company’s 2017 acquisition by Gilead Science.
Earlier this month, the company announced a $50 million financing agreement with NovaQuest Capital for the continued development and commercialization of its treatment for acute Graft versus host disease.
Shares in Mesoblast
(ASX:MSB) are trading are trading 0.64 per cent lower to $1.55
